Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 3/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144558 | 0.92 | MCHR1 (0.41) | DAGLAMCHR1HRH3 | |
| SCHEMBL4134993 | 0.89 | FAAH (0.38) | MCHR1 | |
| SCHEMBL4135208 | 0.83 | KEAP1 (0.39) | DAGLAMCHR1KEAP1NFE2L2OTUD7B | |
| SCHEMBL4136377 | 0.81 | HRH3 (0.52) | DAGLAMCHR1KEAP1NFE2L2OTUD7B | |
| SCHEMBL4136371 | 0.81 | HRH3 (0.52) | DAGLAMCHR1KEAP1NFE2L2OTUD7B | |
| SCHEMBL4136270 | 0.81 | BACE1 (0.38) | HRH3 | |
| SCHEMBL4133535 | 0.81 | HRH3 (0.43) | MCHR1HRH3 | |
| SCHEMBL4136231 | 0.78 | HRH3 (0.45) | MCHR1KEAP1NFE2L2OTUD7BHRH3 | |
| SCHEMBL4140997 | 0.78 | USP30 (0.39) | HRH3 | |
| SCHEMBL4136050 | 0.77 | CASP3 (0.39) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | DAGLA 3031/4885MCHR1 287/4885KEAP1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.